KCT0009438尚未招募Unknown
A phase II study of oral paclitaxel (Liporaxel) in GIST patients with a low P-glycoprotein expression after failure with imatinib, sunitinib and regorafenib
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Age 20 years or older, at the time of acquisition of informed consent
- •2) Histologically confirmed metastatic and/or advanced GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRa gene
- •3) Failed (progressed and/or intolerable) after prior treatments for GIST, including at least imatinib and sunitinib, regorafenib.
- •4) Adequate tissue obtained after treatment failure to imatinib, sunitinib, and regorafenib for P-glycoprotein immunohistochemistry (IHC) analysis, and showed P-glycoprotein expression of less than 6. (For patients with PDGFRa D842V mutation or other subtypes with poor response to tyrosine kinase inhibitors, tumor tissue obtained at any period can be used.)
- •5) Eastern Cooperative Oncology Group (ECOG) performance status 0~2
- •6) Resolution of all toxic effects of prior treatments to grade 0 or 1 by NCI-CTCAE version 5.0
- •7) At least one measurable lesion as defined by RECIST version 1.1.
- •8) Adequate bone marrow, hepatic, renal, and other organ functions
- •-Neutrophil >1,500/mm3
- •-Platelet > 100,000/mm3
- •-Hemoglobin >8.0 g/dL
- •-Total bilirubin < 1.5 x upper limit of normal (ULN)
- •-AST/ALT < 2.5 x ULN
- •-Creatinine <1.5 x ULN
- •9) Life expectancy > 12 weeks
- •10) Washout period of previous TKIs or chemotherapy for more than 4 times the half life ((Imitinib and regorafenib need 1 week and sunitinib need 2 weeks.)
- •11) Provision of a signed written informed consent
排除标准
- •1)Women of child-bearing potential who are pregnant or breast feeding
- •2) Women or men who are not willing to use effective contraception entering the study period or until at least 3 months after the last study drug administration.
- •3) If any of the following applies within = 6 months prior to starting study enrollment : Myocardial Infarction, severe instable angina, coronary/peripheral bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, treatment required severe arrhythmia.
- •4) Uncontrolled infection
- •5) Diabetes mellitus with clinically significant peripheral artery disease
- •6) Acute and chronic liver disease and all chronic liver impairment.(But Patients with stable chronic hepatitis B are eligible)
- •7) Uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2
- •8) Acute, or chronic medical or psychiatric condition or laboratory abnormality such as active uncontrolled infection that difficult to study participation in the judgment of the investigator
- •9) The patient experienced any bleeding episode considered life-threatening, or any grade 3 or 4 bleedig event. (required transfusion or endoscopic or surgical intervention)
- •10) Patient who underwent major surgery or is under recovery from surgery within 28 days from the study treatment
- •11) Known diagnosis of HIV infection (HIV testing is not mandatory).
- •12) History of another primary malignancy that is currently clinically significant or currently requires active intervention.
- •13) Patients with clinically suspected brain metastasis symptom, brain metastases as assessed by radiologic imaging.
- •14) Alcohol or substance abuse disorder.
- •15) Known severe hypersensitivity to paclitaxel
- •16) Received paclitaxel-based treatment for GIST
研究者
相似试验
招募中
2 期
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35
已完成
2 期
A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapyAdvanced or recurrent esophageal cancerJPRN-UMIN000019230niversity of Miyazaki Hospital25
进行中（未招募）
1 期
A Phase I/II non-comparative Study of Paclitaxel plus Carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancerAdvanced, recurrent epithelial ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033160Term: Ovarian epithelial cancer recurrentEUCTR2006-007013-20-DKOnkologisk afdeling R and the Unit for Experimental Chemotherapy70
进行中（未招募）
不适用
A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancerEUCTR2007-005828-32-ATCECOG560
进行中（未招募）
1 期
A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancerEUCTR2007-005828-32-CZCECOG564